Search Results - "Andrews, Jinsy A"

Amyotrophic lateral sclerosis: update on clinical management by Norris, Simone P., Likanje, Marie-France N., Andrews, Jinsy A.

“…The current review will provide recent updates in the clinical management of amyotrophic lateral sclerosis (ALS). Although there is no cure for ALS, there are…”
Get full text

Amyotrophic lateral sclerosis care and research in the United States during the COVID‐19 pandemic: Challenges and opportunities by Andrews, Jinsy A., Berry, James D., Baloh, Robert H., Carberry, Nathan, Cudkowicz, Merit E., Dedi, Brixhilda, Glass, Jonathan, Maragakis, Nicholas J., Miller, Timothy M., Paganoni, Sabrina, Rothstein, Jeffrey D., Shefner, Jeremy M., Simmons, Zachary, Weiss, Michael D., Bedlack, Richard S.

“…Coronavirus disease 2019 has created unprecedented challenges for amyotrophic lateral sclerosis (ALS) clinical care and research in the United States…”
Get full text

Randomized double-blind personalized N-of-1 clinical trial to test the safety and potential efficacy of TJ-68 for treating muscle cramps in amyotrophic lateral sclerosis (ALS): study protocol for a TJ-68 trial by Mitsumoto, Hiroshi, Cheung, Ken, Oskarsson, Björn, Andrews, Howard F, Jang, Grace E, Andrews, Jinsy A, Shah, Jaimin S, Fernandes, Joseph Americo, McElhiney, Martin, Santella, Regina M

“…Muscle cramps are a common and often disabling symptom in amyotrophic lateral sclerosis (ALS), a devastating and incurable neurodegenerative disorder. To date,…”
Get full text

A new era of drug discovery for amyotrophic lateral sclerosis by Andrews, Jinsy A

“…People with amyotrophic lateral sclerosis die on average 3–5 years after diagnosis due to respiratory muscle weakness, which causes respiratory failure.1 The…”
Get full text

Clinical neurophysiology of anterior horn cell disorders by Andrews, Jinsy A, Shefner, Jeremy M

“…The development of neurophysiological techniques for clinical assessment in the 20th century is closely related to the study of anterior horn cell diseases…”
Get more information

Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS by Miller, Timothy M., Cudkowicz, Merit E., Genge, Angela, Shaw, Pamela J., Sobue, Gen, Bucelli, Robert C., Chiò, Adriano, Van Damme, Philip, Ludolph, Albert C., Glass, Jonathan D., Andrews, Jinsy A., Babu, Suma, Benatar, Michael, McDermott, Christopher J., Cochrane, Thos, Chary, Sowmya, Chew, Sheena, Zhu, Han, Wu, Fan, Nestorov, Ivan, Graham, Danielle, Sun, Peng, McNeill, Manjit, Fanning, Laura, Ferguson, Toby A., Fradette, Stephanie

“…The antisense molecule tofersen was tested intrathecally in 108 patients with ALS due to SOD1 mutations. In a subgroup with faster-progressing disease, there…”
Get full text

ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): Study methodology, recruitment, and baseline demographic and disease characteristics by Mitsumoto, Hiroshi, Factor-Litvak, Pam, Andrews, Howard, Goetz, Raymond R., Andrews, Leslie, Rabkin, Judith G., McElhiney, Martin, Nieves, Jeri, Santella, Regina M., Murphy, Jennifer, Hupf, Jonathan, Singleton, Jess, Merle, David, Kilty, Mary, Heitzman, Daragh, Bedlack, Richard S., Miller, Robert G., Katz, Jonathan S., Forshew, Dallas, Barohn, Richard J., Sorenson, Eric J., Oskarsson, Bjorn, Fernandes Filho, J. Americo M., Kasarskis, Edward J., Lomen-Hoerth, Catherine, Mozaffar, Tahseen, Rollins, Yvonne D., Nations, Sharon P., Swenson, Andrea J., Shefner, Jeremy M., Andrews, Jinsy A., Koczon-Jaremko, Boguslawa A.

“…Abstract In a multicenter study of newly diagnosed ALS patients without a reported family history of ALS, we are prospectively investigating whether markers of…”
Get full text

Access to investigational drugs for patients with amyotrophic lateral sclerosis in the USA by Lynch, Holly Fernandez, Morris, Sandra, Andrews, Jinsy A

“…[...]funds are directed to expanded access provided by small companies, without offering a windfall to larger pharmaceutical companies. [...]site…”
Get full text

Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis by Andrews, Jinsy A., Jackson, Carlayne E., Heiman-Patterson, Terry D., Bettica, Paolo, Brooks, Benjamin Rix, Pioro, Erik P.

“…To compare the effect of riluzole on median survival in population studies of patients with amyotrophic lateral sclerosis (ALS) with that observed in clinical…”
Get full text

ALS drug development guidances and trial guidelines: Consensus and opportunities for alignment by Andrews, Jinsy A, Bruijn, Lucie I, Shefner, Jeremy M

“…The US Food and Drug Administration (FDA) developed a draft guidance for drug development in amyotrophic lateral sclerosis (ALS) that was issued in February…”
Get full text

Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study by Benatar, Michael, Wuu, Joanne, Andersen, Peter M., Bucelli, Robert C., Andrews, Jinsy A., Otto, Markus, Farahany, Nita A., Harrington, Elizabeth A., Chen, Weiping, Mitchell, Adele A., Ferguson, Toby, Chew, Sheena, Gedney, Liz, Oakley, Sue, Heo, Jeong, Chary, Sowmya, Fanning, Laura, Graham, Danielle, Sun, Peng, Liu, Yingying, Wong, Janice, Fradette, Stephanie

“…Despite extensive research, amyotrophic lateral sclerosis (ALS) remains a progressive and invariably fatal neurodegenerative disease. Limited knowledge of the…”
Get full text

CK‐2127107 amplifies skeletal muscle response to nerve activation in humans by Andrews, Jinsy A., Miller, Timothy M., Vijayakumar, Vipin, Stoltz, Randall, James, Joyce K., Meng, Lisa, Wolff, Andrew A., Malik, Fady I.

“…ABSTRACT Introduction Three studies evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of CK‐2127107 (CK‐107), a next‐generation fast…”
Get full text

The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis by Salmon, Kristiana, Kiernan, Matthew C, Kim, Seung H, Andersen, Peter M, Chio, Adriano, van den Berg, Leonard H, Van Damme, Philip, Al-Chalabi, Ammar, Lillo, Patricia, Andrews, Jinsy A, Genge, Angela

“…Several genetically-targeted therapies are being developed for ALS. Research is increasingly supportive of a greater incidence of clinically actionable…”
Get full text

Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers: A Review by Shefner, Jeremy M, Bedlack, Richard, Andrews, Jinsy A, Berry, James D, Bowser, Robert, Brown, Robert, Glass, Jonathan D, Maragakis, Nicholas J, Miller, Timothy M, Rothstein, Jeffrey D, Cudkowicz, Merit E

“…Clinical trial activity in amyotrophic lateral sclerosis (ALS) is dramatically increasing; as a result, trial modifications have been introduced to improve…”
Get more information

Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis by Andrews, Jinsy A, Meng, Lisa, Kulke, Sarah F, Rudnicki, Stacy A, Wolff, Andrew A, Bozik, Michael E, Malik, Fady I, Shefner, Jeremy M

“…The prognostic value of slow vital capacity (SVC) in relation to respiratory function decline and disease progression in patients with amyotrophic lateral…”
Get more information

Respiratory measures in amyotrophic lateral sclerosis by Lechtzin, Noah, Cudkowicz, Merit E., de Carvalho, Mamede, Genge, Angela, Hardiman, Orla, Mitsumoto, Hiroshi, Mora, Jesus S., Shefner, Jeremy, Van den Berg, Leonard H., Andrews, Jinsy A.

“…Objective: Amyotrophic lateral sclerosis (ALS) is a progressive neuromuscular disease that causes skeletal muscle weakness, including muscles involved with…”
Get full text

Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study by Rudnicki, Stacy A., Andrews, Jinsy A., Duong, Tina, Cockroft, Bettina M., Malik, Fady I., Meng, Lisa, Wei, Jenny, Wolff, Andrew A., Genge, Angela, Johnson, Nicholas E., Tesi-Rocha, Carolina, Connolly, Anne M., Darras, Basil T., Felice, Kevin, Finkel, Richard S., Shieh, Perry B., Mah, Jean K., Statland, Jeffrey, Campbell, Craig, Habib, Ali A., Kuntz, Nancy L., Oskoui, Maryam, Day, John W.

“…This phase 2, double-blind, placebo-controlled, hypothesis-generating study evaluated the effects of oral reldesemtiv , a fast skeletal muscle troponin…”
Get full text

Medical therapies for amyotrophic lateral sclerosis-related respiratory decline: an appraisal of needs, opportunities and obstacles by Young, Carolyn, Pinto, Susana, Grosskreutz, Julian, Hardiman, Orla, Clawson, Lora L, Cudkowicz, Merit E, Andrews, Jinsy A

“…A roundtable convened in July 2020 examined issues concerning respiratory support in amyotrophic lateral sclerosis (ALS), with reference to the potential for…”
Get full text

A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS by Shefner, Jeremy M., Andrews, Jinsy A., Genge, Angela, Jackson, Carlayne, Lechtzin, Noah, Miller, Timothy M., Cockroft, Bettina M., Meng, Lisa, Wei, Jenny, Wolff, Andrew A., Malik, Fady I., Bodkin, Cynthia, Brooks, Benjamin R., Caress, James, Dionne, Annie, Fee, Dominic, Goutman, Stephen A., Goyal, Namita A., Hardiman, Orla, Hayat, Ghazala, Heiman-Patterson, Terry, Heitzman, Daragh, Henderson, Robert D., Johnston, Wendy, Karam, Chafic, Kiernan, Matthew C., Kolb, Stephen J., Korngut, Lawrence, Ladha, Shafeeq, Matte, Genevieve, Mora, Jesus S., Needham, Merrilee, Oskarsson, Bjorn, Pattee, Gary L., Pioro, Erik P., Pulley, Michael, Quan, Dianna, Rezania, Kourosh, Schellenberg, Kerri L., Schultz, David, Shoesmith, Christen, Simmons, Zachary, Statland, Jeffrey, Sultan, Shumaila, Swenson, Andrea, Berg, Leonard H. Van Den, Vu, Tuan, Vucic, Steve, Weiss, Michael, Whyte-Rayson, Ashley, Wymer, James, Zinman, Lorne, Rudnicki, Stacy A.

“…To evaluate safety, dose response, and preliminary efficacy of reldesemtiv over 12 weeks in patients with amyotrophic lateral sclerosis (ALS). Methods:…”
Get full text

A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis by Shefner, Jeremy M., Wolff, Andrew A., Meng, Lisa, Bian, Amy, Lee, Jacqueline, Barragan, Donna, Andrews, Jinsy A.

“…Our objectives were to evaluate the safety and tolerability of tirasemtiv over 12 weeks and its effect on the revised ALS Functional Rating Scale (ALSFRS-R)…”
Get full text